{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:56:32Z","timestamp":1789394192566,"version":"build-2803163510"},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T00:00:00Z","timestamp":1499904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Verax Biomedical, Incorporated"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Bacterially contaminated platelets (PLTs) remain a serious risk. The Food and Drug Administration has issued draft guidance recommending hospitals implement secondary testing or transfuse PLTs that have been treated with pathogen reduction technology (PRT). The cost implications of these approaches are not well understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN AND METHODS<\/jats:title><jats:p>We modeled incurred costs when hospitals acquire, process, and transfuse PLTs that are PRT treated with INTERCEPT (Cerus Corp.) or secondary tested with the PLT PGD Test (Verax Biomedical).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Hospitals will spend $221.27 (30.0%) more per PRT\u2010treated apheresis PLT unit administered compared to a Zika\u2010tested apheresis PLT unit that is irradiated and PGD tested in hospital. This difference is reflected in PRT PLT units having: 1) a higher hospital purchase price ($100.00 additional charge compared to an untreated PLT); 2) lower therapeutic effectiveness than untreated PLTs among hematologic\u2010oncologic patients, which contributes to additional transfusions ($96.05); or 3) fewer PLT storage days, which contributes to higher outdating cost from expired PLTs ($67.87). Only a small portion of the incremental costs for PRT\u2010treated PLTs are offset by costs that may be avoided, including primary bacterial culture, secondary bacterial testing ($26.65), hospital irradiation ($8.50), Zika testing ($4.47), and other costs ($3.03).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>The significantly higher cost of PRT\u2010treated PLTs over PGD\u2010tested PLTs should interest stakeholders. For hospitals that outdate PLTs, savings associated with expiration extension to 7 days by adding PGD testing will likely be substantially greater than the cost of implementing PGD\u2010testing. Our findings might usefully inform a hospital's decision to select a particular blood safety approach.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.14216","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T15:00:10Z","timestamp":1499958010000},"page":"2321-2328","source":"Crossref","is-referenced-by-count":25,"title":["Addressing the risk of bacterial contamination in platelets: a hospital economic perspective"],"prefix":"10.1111","volume":"57","author":[{"given":"Justin W.","family":"Li","sequence":"first","affiliation":[{"name":"Dobson DaVanzo &amp; Associates, LLC Vienna Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Brecher","sequence":"additional","affiliation":[{"name":"Laboratory Corporation of America Holdings Burlington North Carolina"},{"name":"University of North Carolina at Chapel Hill School of Medicine Chapel Hill North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"New York University School of Medicine New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Harm","sequence":"additional","affiliation":[{"name":"University of Vermont Medical Center Burlington Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Chen","sequence":"additional","affiliation":[{"name":"Dobson DaVanzo &amp; Associates, LLC Vienna Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"El\u2010Gamil","sequence":"additional","affiliation":[{"name":"Dobson DaVanzo &amp; Associates, LLC Vienna Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al","family":"Dobson","sequence":"additional","affiliation":[{"name":"Dobson DaVanzo &amp; Associates, LLC Vienna Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Mintz","sequence":"additional","affiliation":[{"name":"Verax Biomedical, Incorporated Marlborough Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,13]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion. Draft guidance for industry [Internet]. Silver Spring (MD): U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research;2016Mar [cited 2017 Jan 09]. Available from:http:\/\/www.fda.gov\/downloads\/Guidances\/Blood\/UCM425952.pdf."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03308.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-655944"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13676"},{"key":"e_1_2_7_6_1","unstructured":"Revised recommendations for reducing the risk of Zika virus transmission by blood and blood components. Guidance for industry. Silver Spring (MD): U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research;2016Aug [cited 2016 Oct 4]. Available from:http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Blood\/UCM518213.pdf"},{"key":"e_1_2_7_7_1","unstructured":"DoggettL MurphyP DeLauroR et al. Letter to The Honorable Dr. Robert M. Califf MD [Internet].2016Aug 11 [cited 2016 Oct 4]. Available from:https:\/\/votesmart.org\/public-statement\/1122791\/letter-to-the-honorable-dr-robert-m-califf-commissioner-of-the-food-and-drug-administration-expand-zika-testing#.WU010evyuM8."},{"key":"e_1_2_7_8_1","unstructured":"DoggettL MurphyP DeLauroR et al. Letter to The Honorable Andrew Slavitt [Internet].2016Aug 11 [cited 2016 Oct 4]. Available from:https:\/\/votesmart.org\/public-statement\/1122796\/letter-to-the-honorable-andrew-slavitt-acting-administrator-of-the-centers-of-medicare-and-medicaid-services-call-to-reimburse-blood-collection-facilities#.WU01-evyuM8."},{"key":"e_1_2_7_9_1","unstructured":"The 2011 national blood collection and utilization survey report [Internet]. Washington (DC): US Department of Health and Human Services Office of the Assistant Secretary for Health [cited2016Oct 4]. Available from:https:\/\/www.aabb.org\/research\/hemovigilance\/bloodsurvey\/Documents\/11-nbcus-report.pdf."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03201.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13149"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02518.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03532.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03539.x"},{"key":"e_1_2_7_15_1","first-page":"213A","article-title":"Estimated financial impact of complying with the FDA Draft Guidance entitled \u201cBacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion","volume":"56","author":"Sorkin EJ","year":"2016","journal-title":"Transfusion"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12386"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.20147"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02460.x"},{"key":"e_1_2_7_19_1","unstructured":"Summary of Safety and Effectiveness Data (SSED) [Internet]. Silver Spring (MD): U.S. Food and Drug Administration;2014[cited 2016 Nov 28]. Available from:http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/PremarketApprovalsPMAs\/UCM431243.pdf."},{"issue":"3","key":"e_1_2_7_20_1","first-page":"CD009072","article-title":"Pathogen\u2010reduced platelets for the prevention of bleeding","author":"Butler C","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08227.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13512"},{"key":"e_1_2_7_23_1","first-page":"172","article-title":"Hemostatic efficacy of pathogen\u2010inactivated blood components","volume":"42","author":"Ramsey G.","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2011.01555.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14042"},{"key":"e_1_2_7_26_1","first-page":"194A","article-title":"Verax platelet PGD test for use in the clinical blood bank setting","volume":"50","author":"Good CE","year":"2010","journal-title":"Transfusion"},{"key":"e_1_2_7_27_1","volume-title":"Medical and clinical laboratory technologists and technicians pay","year":"2015"},{"key":"e_1_2_7_28_1","first-page":"198A","article-title":"Verax platelet PGD test workflow strategy","volume":"56","author":"Vauthrin M","year":"2016","journal-title":"Transfusion"},{"key":"e_1_2_7_29_1","unstructured":"The 2009 national blood collection and utilization survey report [Internet]. Washington (DC): US Department of Health and Human Services Office of the Assistant Secretary for Health [cited2016Oct 4]. Available from:https:\/\/www.aabb.org\/research\/hemovigilance\/bloodsurvey\/Documents\/09-nbcus-report.pdf."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13577"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2007.09.001"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.00639.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4443"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904084"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12083"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.14216","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.14216","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.14216","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.14216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T16:00:17Z","timestamp":1694016017000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.14216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,13]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1111\/trf.14216"],"URL":"https:\/\/doi.org\/10.1111\/trf.14216","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,13]]}}}